MA53003A - Composés - Google Patents
ComposésInfo
- Publication number
- MA53003A MA53003A MA053003A MA53003A MA53003A MA 53003 A MA53003 A MA 53003A MA 053003 A MA053003 A MA 053003A MA 53003 A MA53003 A MA 53003A MA 53003 A MA53003 A MA 53003A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18180758 | 2018-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53003A true MA53003A (fr) | 2021-05-05 |
Family
ID=62837714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053003A MA53003A (fr) | 2018-06-29 | 2019-06-27 | Composés |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12209091B2 (fr) |
| EP (1) | EP3814351A1 (fr) |
| JP (1) | JP7411588B2 (fr) |
| KR (1) | KR20210025535A (fr) |
| CN (1) | CN112437774A (fr) |
| AR (1) | AR115663A1 (fr) |
| AU (1) | AU2019294414B2 (fr) |
| BR (1) | BR112020026450A2 (fr) |
| CA (1) | CA3103166A1 (fr) |
| CL (1) | CL2020003354A1 (fr) |
| CR (1) | CR20200625A (fr) |
| IL (1) | IL279800B2 (fr) |
| MA (1) | MA53003A (fr) |
| MX (1) | MX2020014085A (fr) |
| PE (1) | PE20211388A1 (fr) |
| PH (1) | PH12020552154A1 (fr) |
| SG (1) | SG11202011818YA (fr) |
| TW (1) | TWI833773B (fr) |
| WO (1) | WO2020002487A1 (fr) |
| ZA (1) | ZA202007956B (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020013930A (es) | 2018-06-22 | 2021-03-09 | Hoffmann La Roche | Oligonucleotidos para modular la expresion del canal de sodio dependiente de voltaje alfa subunidad 9 (scn9a). |
| CN113993591A (zh) * | 2019-06-21 | 2022-01-28 | 豪夫迈·罗氏有限公司 | 新egfr抑制剂 |
| CN114008049B (zh) * | 2019-06-21 | 2024-07-05 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的egfr抑制剂 |
| IL326879A (en) | 2019-11-11 | 2026-04-01 | Dana Farber Cancer Inst Inc | EGFR allosteric inhibitors and methods of using them |
| BR112022011827A2 (pt) | 2019-12-20 | 2022-08-30 | C4 Therapeutics Inc | Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção |
| AR120799A1 (es) * | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr |
| CN115811977A (zh) * | 2020-06-09 | 2023-03-17 | 达纳-法伯癌症研究所股份有限公司 | 变构egfr抑制剂及其使用方法 |
| CN116600806A (zh) * | 2020-12-01 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 新的吲唑衍生物 |
| PE20240099A1 (es) * | 2020-12-01 | 2024-01-18 | Hoffmann La Roche | Nuevos derivados de indazol acetileno |
| JP7840324B2 (ja) * | 2020-12-01 | 2026-04-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| JP2024521791A (ja) * | 2021-05-26 | 2024-06-04 | シーフォー セラピューティクス， インコーポレイテッド | 脳又はｃｎｓへの癌転移を治療するためのｅｇｆｒデグレーダー |
| US20250129047A1 (en) | 2021-07-04 | 2025-04-24 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| CA3232764A1 (fr) | 2021-09-30 | 2023-04-06 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Derive de pyrrolo benzodiazepine, et conjugue, procede de preparation et utilisation de ceux-ci |
| EP4648765A1 (fr) * | 2023-01-11 | 2025-11-19 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs d'egfr sélectifs selon les mutants |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2653222A1 (fr) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Composes de triazole qui modulent l'activite de la hsp90 |
| EP2049518B1 (fr) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Derives de l'indazole et de l'isoindazole comme agents de l'activation de glucokinase |
| ES2408932T3 (es) | 2008-06-25 | 2013-06-24 | Merck Sharp & Dohme Corp. | Síntesis y uso de agentes antibacterianos heterocíclicos |
| EP2536706B1 (fr) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Dérivés d'arylméthoxyisoindoline et compositions les comprenant et leurs procédés d'utilisation |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CN102093339B (zh) | 2010-12-09 | 2013-06-12 | 天津药物研究院 | 一类嘧啶衍生物的制备及用途 |
| CN102060848B (zh) | 2010-12-09 | 2013-09-18 | 天津药物研究院 | 芳香胺取代的嘧啶衍生物的制备及用途 |
| AU2016262572B2 (en) | 2015-05-14 | 2020-04-30 | The Wistar Institute Of Anatomy And Biology | EBNA1 inhibitors and methods using same |
| CA2987914C (fr) | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs d'egfr et methodes d'utilisation de ceux-ci |
| TW201834651A (zh) * | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| WO2018220149A1 (fr) * | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Composés |
-
2019
- 2019-06-27 SG SG11202011818YA patent/SG11202011818YA/en unknown
- 2019-06-27 MX MX2020014085A patent/MX2020014085A/es unknown
- 2019-06-27 JP JP2020573326A patent/JP7411588B2/ja active Active
- 2019-06-27 WO PCT/EP2019/067111 patent/WO2020002487A1/fr not_active Ceased
- 2019-06-27 IL IL279800A patent/IL279800B2/en unknown
- 2019-06-27 CA CA3103166A patent/CA3103166A1/fr active Pending
- 2019-06-27 AU AU2019294414A patent/AU2019294414B2/en active Active
- 2019-06-27 KR KR1020207037595A patent/KR20210025535A/ko not_active Ceased
- 2019-06-27 BR BR112020026450-4A patent/BR112020026450A2/pt not_active Application Discontinuation
- 2019-06-27 MA MA053003A patent/MA53003A/fr unknown
- 2019-06-27 PE PE2020002105A patent/PE20211388A1/es unknown
- 2019-06-27 CN CN201980043788.5A patent/CN112437774A/zh active Pending
- 2019-06-27 EP EP19733493.1A patent/EP3814351A1/fr active Pending
- 2019-06-27 CR CR20200625A patent/CR20200625A/es unknown
- 2019-06-28 TW TW108122864A patent/TWI833773B/zh active
- 2019-07-01 AR ARP190101843A patent/AR115663A1/es not_active Application Discontinuation
-
2020
- 2020-11-25 US US17/105,060 patent/US12209091B2/en active Active
- 2020-12-14 PH PH12020552154A patent/PH12020552154A1/en unknown
- 2020-12-18 ZA ZA2020/07956A patent/ZA202007956B/en unknown
- 2020-12-22 CL CL2020003354A patent/CL2020003354A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL279800A (en) | 2021-03-01 |
| AU2019294414B2 (en) | 2023-06-29 |
| CR20200625A (es) | 2021-02-05 |
| JP2021529775A (ja) | 2021-11-04 |
| US20210079005A1 (en) | 2021-03-18 |
| WO2020002487A1 (fr) | 2020-01-02 |
| AR115663A1 (es) | 2021-02-10 |
| KR20210025535A (ko) | 2021-03-09 |
| IL279800B1 (en) | 2023-10-01 |
| PE20211388A1 (es) | 2021-07-27 |
| CN112437774A (zh) | 2021-03-02 |
| TW202019930A (zh) | 2020-06-01 |
| IL279800B2 (en) | 2024-02-01 |
| MX2020014085A (es) | 2021-03-09 |
| CA3103166A1 (fr) | 2020-01-02 |
| PH12020552154A1 (en) | 2021-07-05 |
| US12209091B2 (en) | 2025-01-28 |
| BR112020026450A2 (pt) | 2021-03-23 |
| EP3814351A1 (fr) | 2021-05-05 |
| JP7411588B2 (ja) | 2024-01-11 |
| ZA202007956B (en) | 2021-10-27 |
| AU2019294414A1 (en) | 2020-12-24 |
| CL2020003354A1 (es) | 2021-07-19 |
| SG11202011818YA (en) | 2020-12-30 |
| TWI833773B (zh) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| MA52948A (fr) | Composés | |
| IL292753A (en) | Compounds | |
| MA51669A (fr) | Composés | |
| EP3720430A4 (fr) | Composés benzocarbonyle | |
| IL283692A (en) | Novel composition | |
| EP3802467A4 (fr) | Composés spirocycliques | |
| EP3941898C0 (fr) | Composés fongicides | |
| EP3691623A4 (fr) | Composés de benzosulfonyle | |
| MA52489A (fr) | Nouveaux composés | |
| EP3956033A4 (fr) | Composés bicycliques | |
| EP3781156A4 (fr) | Composés spirocycliques | |
| MA53003A (fr) | Composés | |
| EP4054724A4 (fr) | Composés bifonctionnels | |
| MA49701A (fr) | Composés immunomodulateurs | |
| EP3740487A4 (fr) | Composés benzamide | |
| DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
| EP3853210A4 (fr) | Composés antibactériens | |
| MA50504A (fr) | Composés antibactériens | |
| EP3728289A4 (fr) | Composés optimisés | |
| EP3464336A4 (fr) | Composés | |
| EP4077318A4 (fr) | Composés | |
| MA52946A (fr) | Composés | |
| DK3808747T3 (da) | Imidazopyridinon-forbindelse | |
| LT3867247T (lt) | Naujieji junginiai |